Development of a novel assay for proprotein converting enzyme activity on a multiplex bead‐based array system

We describe the development of a novel, robust assay system for determining the changes in activity of proprotein converting enzymes. An assay for prolyl oligopeptidase (POP) activity was constructed using a peptide‐streptavidin substrate coupled to magnetic microspheres and cleavage was detected by loss of streptavidin on the MAGPIX reader. Test analysis of postmortem pituitary extracts from schizophrenia patients showed an increase in POP activity compared to controls. The results were validated using both fluorometric and Western blot analyses for POP activity and immunoreactivity, respectively. The assays can be multiplexed for measuring the activity of multiple proprotein cleaving enzymes simultaneously in laboratory and clinical settings and should add valuable new information for conditions such as neuropsychiatric diseases, diabetes, endocrine dysfunction, and cancer, where effects on proteolysis of biologically active peptides play a key role.

[1]  P. Guest,et al.  Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects , 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[2]  Michael D. Spain,et al.  Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia , 2011, Psychoneuroendocrinology.

[3]  D. Steiner On the discovery of precursor processing. , 2011, Methods in molecular biology.

[4]  L. Fricker,et al.  Quantitative peptidomics of mice lacking peptide-processing enzymes. , 2011, Methods in molecular biology.

[5]  Piotr Cieplak,et al.  Substrate Cleavage Analysis of Furin and Related Proprotein Convertases , 2008, Journal of Biological Chemistry.

[6]  A. Bicknell The Tissue‐Specific Processing of Pro‐Opiomelanocortin , 2008, Journal of neuroendocrinology.

[7]  M. Spain,et al.  Key factors in evaluating potential clinical biomarkers. , 2007, IDrugs : the investigational drugs journal.

[8]  J. A. García-Horsman,et al.  On the role of prolyl oligopeptidase in health and disease , 2007, Neuropeptides.

[9]  D. Vignali Multiplexed particle-based flow cytometric assays. , 2000, Journal of immunological methods.

[10]  J. Calabrese,et al.  Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs , 1995, Psychiatry Research.

[11]  H. Meltzer,et al.  Lower serum prolyl endopeptidase enzyme activity in major depression: Further evidence that peptidases play a role in the pathophysiology of depression , 1994, Biological Psychiatry.

[12]  G. Vanhoof,et al.  A sensitive method for the assay of serum prolyl endopeptidase. , 1992, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[13]  A. Porter,et al.  Purification and characterization of human brain prolyl endopeptidase. , 1991, The Biochemical journal.